court ruling on tirzepatide Lilly Wins Battle Against Compounders as Judge Backs FDA: No Longer in Shortage Judge hands win to FDA,

cardiovascular risk)

"Having a biosimilar, which is made by an entirely new pharmaceutical company and maybe made in a more cost-effective way would also relieve some pressures on any future shortages that we might expect," Bajaj said

Lopez-Alarcon 2014

This therapeutic approach is based on a gas treatment that induces the production of ROS/RNS able to specifically target cancer cells

Excellent quality product and easy service Consistent and easy to use

Exclusivity: NCE, Biologics, Orphan, and Pediatric New Chemical Entity exclusivity grants five years of data exclusivity to a drug containing an active moiety never before approved by the FDA